A five-year strategic research collaboration between AstraZeneca and its global biologics research and development arm MedImmune and Ethris, a company focussed on mRNA-based therapeutics with specific expertise in pulmonary disease.
The ProxiSure laparoscopic suturing device was launched, said Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon.
Pfizer’s Besponsa has been approved by the US Food and Drug Administration (FDA). It's the first and only CD22-directed antibody-drug conjugate indicated to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
MyoVista hsECG testing device has been developed for front-line screening of cardiac disease in both symptomatic and asymptomatic patients.
A new nerve-illuminating tool has been developed by researchers and they claim it makes nerves stand out from other tissue, lighting it up to help surgeons avoid accidentally injuring nerves and identify nerves in need of repair.
NeoSync has announced the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13m.
Camber Spine Technologies' Spira open matrix anterior lumbar interbody fusion device won FDA clearance from the FDA.
Being set to supply ingredients for around 400 million vaccines a year, a new £44 million aluminium salts facilityhas been officially opened by GlaxoSmithKline in Montrose, Scotland.
New treatments for neurodegenerative disease and motion disability will be developed by a research collaboration between digital healthcare solutions provider MC10 and US-based rehabilitation research hospital, Shirley Ryan AbilityLab.
Vascular focused device developer VentureMed said today it raised $15 million in a Series B round.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.